- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.
EP: 1.The Pathophysiology of Chronic Spontaneous Urticaria
EP: 2.Hallmark Symptoms of Chronic Spontaneous Urticaria
EP: 3.The Epidemiology Associated With Chronic Spontaneous Urticaria
EP: 4.Differential Diagnosis When Considering Chronic Spontaneous Urticaria
EP: 5.Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria
EP: 6.Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous Urticaria
EP: 7.Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
EP: 8.The Use of Systemic Corticosteroids In Chronic Spontaneous Urticaria Treatment
EP: 9.Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments
EP: 10.Key Updates Needed in Chronic Spontaneous Urticaria Guidelines
EP: 11.The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
EP: 12.Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
EP: 13.Patient Education, Provider Education, and Overall Final Thoughts
Video content above is prompted by the following question:
- Where do you see certain prescriptions fitting into treatment algorithms for patients living with chronic spontaneous urticaria (CSU)?
a. Given the data you’ve seen to date, how would you advise managed
- Another Bruton tyrosine kinase inhibitor, rilzabrutinib, is also under investigation for patients living with CSU. What stage of development is this molecule in and what has the data demonstrated?
- How do you see treatment algorithms changing in the future with the introduction of newer classes of therapies?
a. With potential new treatment options on the horizon, how do you think payers should anticipate covering CSU in the next few years?
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More
Redesigning Inpatient Dermatology to Address Costs, Improve Access
February 20th 2025The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to improve care, reduce costs, and address health equity for patients with skin diseases.
Read More
AI-Enabled Wearable Sensor Reduces Scratching in Atopic Dermatitis
February 11th 2025Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep behaviors.
Read More
Dermocosmetics as Adjunctive Therapy Reduces Sensitivity and Improves Quality of Life in Acne
January 22nd 2025Dermocosmetics alongside traditional acne treatments improved skin tolerance and reduced acne severity in patients, particularly those using retinoids, leading to enhanced quality of life.
Read More
